Show simple item record

dc.contributor.authorDEV, KUMLESH
dc.date.accessioned2011-10-10T15:46:54Z
dc.date.available2011-10-10T15:46:54Z
dc.date.issued2011
dc.date.submitted2011en
dc.identifier.citationClaus Rieker, Kumlesh K. Dev, Katja Lehnhoff, Samuel Barbieri, Iwona Ksiazek, Sabine Kauffmann, Simone Danner, Heinrich Schell, Cindy Boden, Markus A. Ruegg, Philipp J. Kahle, Herman van der Putten, Derya R. Shimshek, Neuropathology in Mice Expressing Mouse Alpha-Synuclein, PLoS ONE, 6, 9, e24834, 2011en
dc.identifier.otherY
dc.descriptionPUBLISHEDen
dc.description.abstract?-Synuclein (?SN) in human is tightly linked both neuropathologically and genetically to Parkinson's disease (PD) and related disorders. Disease-causing properties in vivo of the wildtype mouse ortholog (m?SN), which carries a threonine at position 53 like the A53T human mutant version that is genetically linked to PD, were never reported. To this end we generated mouse lines that express m?SN in central neurons at levels reaching up to six-fold compared to endogenous m?SN. Unlike transgenic mice expressing human wildtype or mutant forms of ?SN, these m?SN transgenic mice showed pronounced ubiquitin immunopathology in spinal cord and brainstem. Isoelectric separation of m?SN species revealed multiple isoforms including two Ser129-phosphorylated species in the most severely affected brain regions. Neuronal Ser129-phosphorylated ?SN occured in granular and small fibrillar aggregates and pathological staining patterns in neurites occasionally revealed a striking ladder of small alternating segments staining either for Ser129-phosphorylated ?SN or ubiquitin but not both. Axonal degeneration in long white matter tracts of the spinal cord, with breakdown of myelin sheaths and degeneration of neuromuscular junctions with loss of integrity of the presynaptic neurofilament network in m?SN transgenic mice, was similar to what we have reported for mice expressing human ?SN wildtype or mutant forms. In hippocampal neurons, the m?SN protein accumulated and was phosphorylated but these neurons showed no ubiquitin immunopathology. In contrast to the early-onset motor abnormalities and muscle weakness observed in mice expressing human ?SN, m?SN transgenic mice displayed only end-stage phenotypic alterations that manifested alongside with neuropathology. Altogether these findings show that increased levels of wildtype m?SN does not induce early-onset behavior changes, but drives end-stage pathophysiological changes in murine neurons that are strikingly similar to those evoked by expression of human wildtype or mutant forms.en
dc.description.sponsorshipThe study was funded by Novartis Pharma AG, who, through the employment of Claus Rieker, Katja Lehnhoff, Samuel Barbieri, Sabine Kauffmann, Simone Danner Herman van der Putten and Derya Shimshek, had a role in conceiving, designing and performing the experiments and analyzing the data.en
dc.language.isoenen
dc.publisherPLoSen
dc.relation.ispartofseriesPLoS ONE;
dc.relation.ispartofseries6;
dc.relation.ispartofseries9, e24834;
dc.rightsYen
dc.subjectNeuroscienceen
dc.subjectParkinson's Diseaseen
dc.titleNeuropathology in Mice Expressing Mouse Alpha-Synucleinen
dc.typeJournal Articleen
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/devk
dc.identifier.rssinternalid75328
dc.identifier.rssurihttp://dx.doi.org/10.1371/journal.pone.0024834en
dc.identifier.urihttp://hdl.handle.net/2262/60009


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record